Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test

Executive Summary

'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.

Advertisement

Related Content

Esperion Posts Positive Phase III Bempedoic Acid Results, But Future Fixed-Dose Data Are Key
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
PCSK9 Add-On Study Helps Esperion Cover All The Bases With Bempedoic Acid
Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Novartis Aims Canakinumab At Targeted CV Patients
Esperion Expects Speedy Regulatory Path For Bempedoic Acid/Zetia Combo
CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron
Esperion Says FDA On Board With Filing Strategy For Bempedoic Acid
Crestor Label Lends Validity To Controversial C-Reactive Protein Test

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel